Angiopoietin-2: development of inhibitors for cancer therapy. - Wikidata - awgldk - TriplyDB

Angiopoietin-2: development of inhibitors for cancer therapy.

Angiopoietin-2: development of inhibitors for cancer therapy.

http://www.wikidata.org/entity/Q33839423

about

Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy Delineating the angiogenic gene expression profile before pulmonary vascular remodeling in a lamb model of congenital heart disease.Vaccines targeting the neovasculature of tumors Array-based discovery of aptamer pairs Quantitative selection and parallel characterization of aptamers.Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway.Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer.Angiopoietin-2, an angiogenic regulator, promotes initial growth and survival of breast cancer metastases to the lung through the integrin-linked kinase (ILK)-AKT-B cell lymphoma 2 (Bcl-2) pathway What role for angiogenesis in childhood acute lymphoblastic leukaemia?Elevated peripheral blood plasma concentrations of tie-2 and angiopoietin 2 in patients with neuroendocrine tumors.Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617.Gastric tumour-derived ANGPT2 regulation by DARPP-32 promotes angiogenesis Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.Tubeimoside-1 suppresses tumor angiogenesis by stimulation of proteasomal VEGFR2 and Tie2 degradation in a non-small cell lung cancer xenograft model Expression of angiopoietin-TIE system components in angiosarcoma Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?MiR-145 functions as a tumor suppressor via regulating angiopoietin-2 in pancreatic cancer cells.Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.Angiogenesis in cancer: Anti-VEGF escape mechanisms Serum biomarker analysis in patients with recurrent spontaneous abortion.Oncogenic function of angiopoietin-2 in vitro and its modulation of tumor progression in colorectal carcinoma.Angiopoietin-2 inhibition using siRNA or the peptide antagonist L1-10 results in antitumor activity in human neuroblastoma.Knockdown of angiopoietin-2 suppresses metastasis in human pancreatic carcinoma by reduced matrix metalloproteinase-2.Pigment epithelium-derived factor (PEDF): a novel trophoblast-derived factor limiting feto-placental angiogenesis in late pregnancy.MicroRNAs miR-125b and miR-100 suppress metastasis of hepatocellular carcinoma by disrupting the formation of vessels that encapsulate tumour clusters.Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis.Association of elevated interleukin-17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia.Angiopoietin-2 is expressed in oral Kaposi's sarcoma.The Role of Angiogenesis in Cancer Treatment.Growth Factor-Free Pre-vascularization of Cell Sheets for Tissue Engineering.The lymphangiogenic factor SOX 18: a key indicator to stage gastric tumor progression.Overexpression of Tie2 is associated with poor prognosis in patients with gastric cancer.Potential suppressive effects of theophylline on human rectal cancer SW480 cells in vitro by inhibiting YKL-40 expression.[The influence of inhibiting angiopoietin-2 on the biological characteristics of bronchogenic adenocarcinoma].Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

P2860

Q26784218-A88464A6-0F4E-4447-B26E-D6E95B6516FA Q31121875-4EEBD638-29B4-4B34-912A-5F1B11897E85 Q33732486-7DF862E5-60FE-48DE-A5A2-B89D9FC39758 Q33898877-264F366C-750F-48F5-8894-BF296C79098D Q34344165-9C0F2C3B-9423-4A30-BADE-92EE23604525 Q34518898-E547F2ED-0A85-4012-BAA3-BDE7C2907489 Q34704905-E90EBD9D-D8B4-4330-9576-58B149562679 Q34879171-AC354CD1-8613-49D9-844D-B5B0FF9F567D Q35027580-84E2CB2C-6C7E-4A14-B39A-2367B36521F8 Q35120530-27560D41-7BD9-4901-899C-C78A0780DAAF Q35144839-4FAD5472-F7B9-40AD-A8E5-FBD0D4FBDC96 Q35310168-A78F2E01-9061-48C0-A3EA-28DBAD175242 Q35550914-6F57B5B3-84EA-484C-844F-A4430864F0A6 Q35795736-632846C8-4636-4797-B92A-A7CF2FA1C62E Q35881597-677C9655-8554-4525-810B-B90C1F5AACD5 Q36069142-312D2A3C-1F17-48A7-B3F7-AADC7C003FD6 Q36831553-DB4B60C8-BA27-4321-AE4F-458AB108F3BB Q36905630-2E7195BD-0027-4061-8296-B0F87EDC35E4 Q36997066-11FE2877-9D79-47D5-82FC-75B95E1CA446 Q37088265-2EEDEF14-D281-4DB8-8CB5-A0D9539F6FE5 Q37209635-73A0E5FF-C269-45BC-86C2-B987C5A5103C Q38239003-6F0C8F3B-1CE2-4F2C-9464-AE66DA495C9C Q38389975-6CAD8495-B4EA-431F-A2DE-5670A8A58C9D Q38693339-57C55201-3921-4C19-9B5F-554560A845BC Q38697673-E439AE4E-B394-4B0B-99B2-28A0C68F4B19 Q39317367-E1F51429-D5BD-49CB-A06B-E7687F56FAC0 Q39372556-626E3440-8DAD-40FD-8CF0-7390BBB8A44F Q39698792-6B0CDD17-7EF9-4A5D-840F-75DC61935E6C Q40536884-3401A339-AF04-44A7-BABC-3359B85FC880 Q42147633-3E6EE512-6ECF-4D6D-A2EE-46147AC4F7CC Q47207790-C89BEFD7-287B-412D-9425-3579C681F399 Q48333282-E1D9C341-410B-4885-B090-C56EA707A5AA Q50932310-DF74C680-4B1E-4B1E-A157-3EFA8C1C1CE2 Q51308312-3BA9F9C4-EF8E-485D-B1A9-1BB8A732A853 Q54356965-E63FD9BA-DC90-4235-9191-E16126B59053 Q54977592-66C83C91-748B-4F63-9431-78A6CD7EC9AF Q55210960-692B36B7-3572-48F9-8433-45A600F2436F Q55444655-9ECD98D7-D2EF-4C85-B2DD-36F4D2B6B778 Q57067866-C00FC89A-332A-46C4-9CB0-3BD8206297FC

P2860

Angiopoietin-2: development of inhibitors for cancer therapy.

http://www.wikidata.org/entity/Q33839423

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Angiopoietin-2: development of inhibitors for cancer therapy.

@ast

Angiopoietin-2: development of inhibitors for cancer therapy.

@en

type

label

Angiopoietin-2: development of inhibitors for cancer therapy.

@ast

Angiopoietin-2: development of inhibitors for cancer therapy.

@en

prefLabel

Angiopoietin-2: development of inhibitors for cancer therapy.

@ast

Angiopoietin-2: development of inhibitors for cancer therapy.

@en

P1433

Q33839423-840D9B26-E07E-4AD0-9DEA-097D73DA56D8

P1476

Q33839423-76EB8B47-7545-41D3-B143-CB622DA1CD9B

P2093

Q33839423-4D12BA6F-1CED-4661-A2D8-3F3208292BDE

Q33839423-D6BE3C44-EF4C-4F17-B945-8D5D8DB47E8D

P2860

Q33839423-024E1C80-DC24-419C-A4B3-35EF6F5324A1

Q33839423-0F3C7D28-E712-475E-B0D8-A9E4D80495B8

Q33839423-11A10609-966C-4D3E-B7D5-FE0DA852617D

Q33839423-1967DF61-7C7D-4FCC-9B03-5051980BEB0D

Q33839423-1CF1E567-421C-4178-AF2C-0E35AB8CD78A

Q33839423-208B9447-6BA1-455B-8CE9-DAE50FEC0177

Q33839423-22721FA4-F873-40D3-AF8E-ACA67733C03B

Q33839423-258717E6-B57E-4CB9-A2DF-1B5220B2AF1D

Q33839423-2C6AD315-D151-4B5E-B90A-57B6990D2715

Q33839423-318A3323-23BF-4CAD-B9A3-C7B7B157C7CC

P2888

Q33839423-5166288B-6F17-45F6-B335-999B95847519

P304

Q33839423-3D4B050A-C38B-40B7-906F-11FCC5B7B6E3

P31

Q33839423-ACBF11E8-6E1D-49E8-8EE1-0FF97D4B3269

P356

Q33839423-8D35D527-6785-4D01-B6BE-8B73899CF35C

P433

Q33839423-CA81ACD4-8B9C-447B-AE62-0078E13E3731

P478

Q33839423-BE4E3456-C5AE-4EF5-BBE7-444EC9AF652E

P577

Q33839423-06AE72B7-1453-42EA-86C0-FC4B3088BF88

P5875

Q33839423-CCAC3930-A1EB-49B5-86A9-6795DB6B1E76

P6179

Q33839423-35F6428D-BD35-4293-8FFD-CEF4AB86D6FB

P698

Q33839423-235AE94D-8C89-4E8C-831B-6960C8F30E8E

P932

Q33839423-58C04F2A-B478-483B-98A4-8E5C668BF9A2

P356

S11912-009-0017-3

P1433

Current Oncology Reports

P1476

Angiopoietin-2: development of inhibitors for cancer therapy.

@en

P2093

Bo Hu

http://www.w3.org/2001/XMLSchema#string

Shi-Yuan Cheng

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

Angiogenesis in cancer and other diseases

Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1

Regulation of angiopoietin and Tie-2 receptor expression in non-reproductive tissues by estrogen

Transcriptional and posttranscriptional regulation of angiopoietin-2 expression mediated by IGF and PDGF in vascular smooth muscle cells

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A

P2888

s11912-009-0017-3

P304

111-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-009-0017-3

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24010091

http://www.w3.org/2001/XMLSchema#string

P6179

1007927088

http://www.w3.org/2001/XMLSchema#string

P698

19216842

http://www.w3.org/2001/XMLSchema#string

P932

2867109

http://www.w3.org/2001/XMLSchema#string